Keefe, Bruyette & Woods Rates Crescent Capital BDC (CCAP) buy
Analyst Paul Johnson of Keefe, Bruyette & Woods reaffirms a buy rating with a $13 price target for Crescent Capital BDC, a 16.23% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Keefe, Bruyette & Woods rated Crescent Capital BDC, Inc. ($CCAP) "buy" with a $13 price target on June 16, 2026.
Since the rating, $CCAP is down 0.8% after 1 week, up 1.7% after 1 month and down 16.0% to date (from the $10.59 close on Jun 16, 2026).
CCAP
Crescent Capital BDC, Inc.
Key Points
- Keefe, Bruyette & Woods reiterated its buy rating on Crescent Capital BDC with a $13 price target as of June 16, 2026.
- Keefe, Bruyette & Woods's $13 price target implies 16.23% upside from Crescent Capital BDC, Inc.'s ($CCAP) current $11.19 share price.
- Crescent Capital BDC trades at $11.12, with a market cap of $418.6 million and a forward P/E of 7.6.
- Insider buying activities include purchases by CEO Jason Breaux and President Henry Chung in May 2026.
Get $CCAP trade alerts by text
We text you when insiders, Congress or big funds trade $CCAP. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Crescent Capital BDC, Inc. alert may contain errors. Disclosures
Keefe, Bruyette & Woods, through analyst Paul Johnson, has reiterated its buy rating on Crescent Capital BDC, Inc. (NasdaqGM: CCAP) as of June 16, 2026. The firm has set a price target of $13 for the stock, which is currently trading at $11.12.
Crescent Capital BDC, Inc. Stock Up 14.4%
Shares of Crescent Capital BDC are trading at $11.12 on the NasdaqGM. The company has a market cap of approximately $418.6 million and a forward P/E ratio of 7.6, indicating how the stock is valued relative to its expected earnings. The stock's 52-week range spans from $10.92 to $16.04, with a 50-day moving average of $12.39 and a 200-day moving average of $13.71. Crescent Capital BDC has a beta of 0.575, suggesting it is less volatile than the broader market.
$CCAP price target
Crescent Capital BDC, Inc. daily closes and this analyst's $13 target. Not advice.
Recent Earnings
Crescent Capital BDC reported revenue of $163.1 million, although it experienced a slight revenue decline of 0.1%. The company achieved a net margin of 9.3% and a return on equity of 2.2%. The next earnings report is expected on August 12, 2026.
Dividend
Crescent Capital BDC offers a robust dividend, with an annual rate of $1.60 per share, yielding 14.08%. The payout ratio stands at 4.2%, indicating the proportion of earnings paid out as dividends.
Insider Buying and Selling at Crescent Capital BDC, Inc.
Several insiders have been buying shares of Crescent Capital BDC recently. On May 21, 2026, President Henry Chung purchased 4,500 shares at an average price of $11.45. CEO Jason Breaux acquired 5,000 shares on May 20, 2026, at $11.19 per share. Additionally, CFO Gerhard Lombard bought 1,000 shares at $11.12 on May 18, 2026. These transactions were not conducted under any pre-planned trading programs.
Analysts Set New Price Targets
On June 16, 2026, Keefe, Bruyette & Woods maintained its buy rating on Crescent Capital BDC with a $13 price target. Other firms have also weighed in recently; on May 15, 2026, Ladenburg Thalmann maintained a buy rating with a $15 target, while Oppenheimer downgraded its rating to buy with a $16 target on the same day. The consensus among seven analysts is a mean price target of $14.
About Crescent Capital BDC
Crescent Capital BDC, Inc. is a business development company focused on private equity and loan funds. Specializing in middle-market investments, Crescent Capital primarily targets opportunities within the United States. Headquartered in Los Angeles, California, the company is led by CEO Jason A. Breaux.
Bottom Line
Keefe, Bruyette & Woods' reaffirmation of its buy rating reflects continued confidence in Crescent Capital BDC's potential. The company's appealing dividend yield and insider buying activities may interest investors. However, it's important to remember that 13F filings and analyst ratings are based on past data and may not represent current positions or future performance.
Related Filing Alerts
Source: Keefe, Bruyette & Woods's rating change on $CCAP (Jun 16, 2026). Written by software, not financial advice. How we make alerts